GUARDION HLTH SCIENCS INC - GHSI STOCK NEWS

Guardion Health Sciences (GHSI) reported a significant revenue increase to $3,148,612 for Q3 2021, up from $253,188 in Q3 2020, primarily driven by the acquisition of the Viactiv brand. However, net loss widened to $(3,014,836), compared to $(2,143,494) a year earlier. Operating expenses also rose to $4,403,545, reflecting the costs associated with the Viactiv integration. Total revenue for the nine months ended September 30, 2021, stood at $4,605,628. Guardion is focusing on expanding Viactiv’s market share amid supply chain challenges.

Guardion Health Sciences, Inc. (Nasdaq: GHSI) announced that CEO Bret Scholtes will present at the Benzinga Global Small Cap Conference on October 27-28, 2021. His presentation is scheduled for October 27 at 1:15 PM ET. Additionally, he will be available for one-on-one meetings during the conference. Guardion focuses on clinically supported nutrition, medical foods, and diagnostic products, aiming to support healthcare professionals and patients in health goals. The company emphasizes its commitment to innovation within the eye care and clinical nutrition industry.

Guardion Health Sciences (GHSI) is taking strategic steps to enhance operational efficiency and market reach. The company will terminate its lease on the San Diego office and warehouse by the end of October, which is projected to lower overhead costs. Additionally, Guardion has launched a redesigned corporate and investor website aimed at boosting stakeholder engagement. CEO Bret Scholtes emphasized the focus on optimizing customer interactions and managing costs effectively, particularly in relation to the recently acquired Viactiv business.

Guardion Health Sciences, Inc. (Nasdaq: GHSI) is urging stockholders to vote their shares ahead of the Annual Meeting scheduled for October 22, 2021. Votes must be submitted by 11:59 PM ET on October 21, 2021. Key proposals include the election of five Directors, auditor approval, and executive compensation approval. Stockholders can contact Kingsdale Advisors for assistance with voting. The Company emphasizes the importance of every vote being counted. Further details are available in the Company's proxy statement.

Guardion Health Sciences, Inc. (Nasdaq: GHSI) will present a corporate overview at the 14th Annual LD Micro Main Event Conference from October 12-14, 2021, in Los Angeles. CEO Bret Scholtes is set to deliver his presentation on October 12 at 9:00 AM PT/12:00 PM ET in track 4. Scholtes will also hold one-on-one meetings during the event. Guardion specializes in clinical nutrition and diagnostics, aiming to support healthcare professionals and consumers with science-based products. For more details, visit the SEC's website regarding Guardion's business and financial risks.

Guardion Health Sciences, Inc. (Nasdaq: GHSI) announced that CEO Bret Scholtes will present at the Benzinga Healthcare Small Cap Conference, held virtually from September 29-30, 2021. Scholtes' presentation is scheduled for September 30 at 11:10 AM ET, and he will also participate in one-on-one meetings during the event. Guardion focuses on clinically supported nutrition, medical foods, supplements, and medical devices, aiming to help healthcare professionals and patients achieve their health goals.

Guardion Health Sciences (GHSI) announced that CEO Bret Scholtes will present at the H.C. Wainwright 23rd Annual Global Investment Conference, taking place virtually from September 13 to September 15, 2021. The presentation will be available starting September 13 at 7:00 AM ET. Investors can register to attend the conference via the provided link. Additionally, Scholtes will be available for one-on-one meetings throughout the event. Guardion focuses on clinical nutrition and diagnostics, offering science-based products to support health goals.

Guardion Health Sciences (GHSI) reported financial results for Q2 and H1 2021, with total revenue of $1,223,720, up 2.8% from Q2 2020. Notably, revenue includes sales from the recently acquired Activ Nutritional, which contributed 86% of total revenue. However, the net loss for Q2 reached $(4,540,288), significantly higher than the previous year's loss of $(707,160), mainly due to acquisition-related costs. The company holds $12,502,677 in cash, with ongoing growth initiatives focused on leveraging the Activ brand and exploring new product opportunities.

Guardion Health Sciences, Inc. (Nasdaq: GHSI) will exhibit at the ASCRS Annual Meeting from July 23-27, 2021, in Las Vegas. This significant eye care event allows Guardion to engage with healthcare professionals about its clinically supported nutrition products and recent Viactiv brand acquisition. CEO Bret Scholtes expressed enthusiasm for reconnecting with industry stakeholders and leveraging post-pandemic marketing initiatives. The company highlights its commitment to scientific and medical integrity, aiming to enhance product visibility and market presence.